Why tibolone is different?

Reviews in Gynaecological Practice

Volumn 2, Issue 1-2, 2002, Pages 35-39

  Rymer, Janice ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

HRT; Hypooestrogenic symptoms; Osteoporosis; Tibolone

Indexed keywords

ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; TIBOLONE;

BREAKTHROUGH BLEEDING; BREAST; BREAST TENDERNESS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIOSIS; ENDOMETRIUM; ESTROGEN THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MOOD; OSTEOLYSIS; POSTMENOPAUSE; PROPHYLAXIS; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; SKELETON; UTERUS; VAGINA SMEAR; VASOMOTOR REFLEX; WEIGHT GAIN;

EID: 14344258238     PISSN: 14717697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-7697(02)00017-5     Document Type: Review

References (36)

1. Kicovic PM, Cortes-Prieto J, Luisi M, et al. Placebo controlled cross-over study of the effects of Org OD14 in post-menopausal women. Reproduction 1982;6:81-91.
2. Tax L, Goorissen EM, Kicovic PM. Clinical profile of Org OD14. Maturitas 1987;(Suppl 1):3-13.
3. Volpe A, Facchinette F, Grasso A, et al. Benefits and risks of different hormonal replacement therapies in post-menopausal women. Maturitas 1986;8:327-34.
4. Milner MH, Sinnott MM, Cooke TM, et al. A 2-year study of lipid and lipoprotein changes in post-menopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996;87:593-9.
5. Rymer J, Chapman MG, Fogelman I, Wilson POG. A study of the effect of tibolone on the vagina in post-menopausal women. Maturitas 1994;18:127-33.
6. Morris EP, Wilson PO, Robinson J, Rymer JM. Long-term effects of tibolone on the genital tract in post-menopausal women. Br J Obstet Gynaecol 1999;106(9):954-9.
7. Sherwin B, Gelfand M, Brender W. Androgen enhances sexual motivation in females: a prospective, cross-over study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47:339-51.
8. Nathorst-Boos J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15-20.
9. Gennazani AR, Benedeck-Jaszman LJ, Hart DM, et al. Effects of Org OD14 on pituitary and β-endorphins in castrated rats and in post-menopausal women. Maturitas 1987;Suppl 1:35-48.
10. Lindsay R, McKay-Hart D, Krazawski A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing post-menopausal osteoporosis. Br Med J 1980;1209-09.
11. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on post-menopausal bone loss. Osteopor Int 1994;4:314-7.
12. Rymer J, Robinson J, Fogelman I. Effects of 8 years' treatment with tibolone 2.5 mg daily on post-menopausal bone loss. Osteopor Int [in press].
13. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late menopausal women. J Clin Endocrinol Metabiol 1997;81:2419-22.
14. Geusens P, Dequeker J, Gielen J, et al. Non-linear increase in vertebral bone density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991;13:155-62.
15. Studd J, Arnala I, Zamblera P, et al. Tibolone increase bone mass in women with previous fractures in a placebo controlled bicentre study. Osteopor Int 1996;6(Suppl 1):230.
16. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures: the study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-5.
17. Kroger H, Huopio I, Honkanen R, et al. Prediction of fracture risk using axial bone mineral density in a peri-menipausal population: a prospective study. J Bone Miner Res 1995;10:302-6.
18. Ederveen AGH, Kloosterboer HJ. Tibolone exerts an estrogenic effect on bone leading to prevention of bone loss and reduction in bone resorption in ovariectomized rats. Osteopor Int 1998;8:95.
19. De Aloysio D, Fabiani AG, Mauloni M, et al. Use of Org OD14 for the treatment of climacteric complaints. Maturitas 1987;(Suppl 1):49-65.
20. Lloyd G, McGing E, Cooper A, Patel N, Lumb PJ, Wierzbicki AS, Jackson G. A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertension 2000;14(2):99-104.
21. Winkler UH, Altkemper R, Kwee B, Helmond FA, Ceolingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multi-centre, double-blind, randomized study. Fertil Steril 2000;74(1):10-9.
22. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metabiol 1997;82:1752-6.
23. Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein (a) in post-menopausal women. Acta Endocrinol 1993;128:259-62.
24. Haenggi W, Lippuner K, Riesen W, et al. Long-term influence of different post-menopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol 1997;104:708-17.
25. Feher MD, Cox A, Levy A, et al. Short-term blood pressure and metabolic effects of tibolone in post-menopausal women with NIDDM. Br J Obstet Gynaecol 1996;103:281-3.
26. Hardiman P, Nihoyannopoulous P, Kicovic P, et al. Cardiovascular effect of Org OD14 - a new steroidal therapy for climecteric symptoms. Maturitas 1991;13:235-42.
27. Haenggi W, Linder HR, Birkhauser MH, et al. Microscopic findings of the nail-fold capillaries - dependence on menopausal status and HRT. Maturitas 1995;22:37-46.
28. Colacurci N, Mele D, De Franciscis P, Costa V, Fortunato N, De Seta L. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 1998;80(2):235-8.
29. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59.
30. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17:135-40.
31. Kloosterboer HJ. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal models of tumours. Gynecol Endocrinol 1997;11(Suppl 1):63-8.
32. Erel CT, Elter K, Akman C, Ersavasti G, Altug A, Seyisoglu H, Ertungealp E. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69(5):870-5.
33. Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994;101:53-6.
34. Andrews WC. Continuous combined estrogen/progestogen HRT. Clin Therap 1995;17:815-26.
35. Lindsay PC, Shaw RW, Coelingh Bennink HJ, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the GnRHa triptorelin. Fertil Steril 1996;65:342-348;; Writing Group for the Women's Health Initiative Investigators Risks and Benefits of Oestrogen Plus Progesterone in Healthy Posv-menopausal Women. JAMA 2002;288(3):321-333.
36. Lindsay PC, Shaw RW, Coelingh Bennink HJ, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the GnRHa triptorelin. Fertil Steril 1996;65:342-348;; Writing Group for the Women's Health Initiative Investigators Risks and Benefits of Oestrogen Plus Progesterone in Healthy Posv-menopausal Women. JAMA 2002;288(3):321-333.